(FILE 'HOME' ENTERED AT 14:50:25 ON 15 SEP 2000)

```
FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 14:50:41 ON 15 SEP 2000
         211053 S HIV
L1
· L2
         297235 S GLYCOPROTEIN#
L3
          15041 S GP120 OR GP160
L4
         713277 S MODIFY OR MODIFIED OR MODIFYING
L5
          47817 S MUTATE OR MUTATED OR MUTATING
L6
         467248 S PLASMID# OR VECTOR#
          36180 S ANTIGEN PRESENTING CELL# OR APC#
L7
          93280 S L7 OR DENDRITIC
L8
L9
          18044 S L1 AND (L2 OR L3)
L10
          11774 S VARIABLE LOOP OR V3
L11
         759169 S L4 OR L5
            708 S L11 AND L9
L12
            149 S L12 AND L10
L13
             14 S L13 AND L6
L14
L15
              8 DUP REM L14 (6 DUPLICATES REMOVED)
L16
            350 S L11 (P)L10
             21 S L16 AND L6
L17
             13 DUP REM L17 (8 DUPLICATES REMOVED)
L18
L19
             12 S L17 NOT L14
             13 DUP REM L18 (0 DUPLICATES REMOVED)
L20
L21
             77 S L11 (10A)L10
L22
              5 S L21 AND L6
L23
              3 DUP REM L22 (2 DUPLICATES REMOVED)
                E YUTARO KANEKO/AU
                E YUTARO, KANEKO/AU
                E KANEKO, YUTARO/AU
                E KANEKO YUTARO/AU
L24
            124 S E3-E4
                E KANEKO Y/AU
L25
           1960 S E3-E7
L26
           2084 S L24 OR L25
L27
             54 S L26 AND L2
L28
              3 S L27 AND L10
L29
          43997 S DELETE OR DELETED OR DELETING
L30
            112 S L10 (P) L29
             19 S L30 AND L6
L31
L32
             11 DUP REM L31 (8 DUPLICATES REMOVED)
```

L4ANSWER 17 OF 17 DLINE The apathogenic leastle disease virus (NDV) strate Ulste successfully as an adjuvant component for active specific Ulster has been used AB · immunotherapy of malignant mouse lymphoma, and in nude mice it was shown to be able to lead to retardation of the s.c. growth of xenotransplanted human melanoma cells. In order to improve in vivo effectiveness of virotherapy of human tumors without significantly increasing the risk of unspecific viral replication in host cells, we adapted the virus for growth in a human melanoma line (MeWo M). For this purpose NDV Ulster was mutagenized and a variant was selected which could replicate and reinfect the tumor line. The mutant (NDV 1E 10) performed late lysis on the melanoma line. Replication was found to be at least 100 times more efficient in MeWo M than in 6 of 8 other human tumor cell lines of different tissue origin. In 10 of 11 murine cell lines, NDV 1E 10 did not replicate via multicycles. Chick embryonic fibroblasts were permissive for

nonlytic replication. Neither the virulent wild-type NDV Italian nor the avirulent strain NDV Ulster shared these specific replication properties with the new variant. We also established MeWo melanoma sublines with different metastatic capacities and tested them as targets for NDV 1E 10 infection. The MeWo subpopulations exhibited comparatively small differences in permissivity for multicyclic replication, but the more metastatic MeWo Met, like allogeneic melanoma lines, was more resistant

lysis. NDV Italian, in contrast, showed no differences in replication and lysis on any of the tested melanoma lines. Trypsin-activation experiments suggested an incomplete cleavage of mutant envelope glycoprotein F by the permissive cell line and, thus, mechanisms of specific infection and replication not requiring fully activated envelope glycoproteins.

CTCheck Tags: Animal; Human *Melanoma: MI, microbiology Mice

Mutation

Neoplasm Metastasis

*Newcastle Disease Virus: IP, isolation & purification

Newcastle Disease Virus: PH, physiology Peptide Hydrolases: PD, pharmacology

T-Lymphocytes: IM, immunology

Tumor Cells, Cultured

Viral Fusion Proteins: AN, analysis

*Virus Replication

=> d his

L1

L2

(FILE 'HOME' ENTERED AT 13:55:01 ON 06 OCT 2000)

FILE 'BIOSIS, MEDLINE' ENTERED AT 13:55:17 ON 06 OCT 2000 278 S ENVELOPE AND GLYCOPROTEIN# AND ADJUVANT# 30 S L1 AND (MUTAT? OR MODIF? OR DELET? OR INSERT?)

22 DUP REM L2 (8 DUPLICATES REMOVED) L3

Ŀ4 17 S L3 NOT PY>1998